FI110687B - Menetelmä valmistaa N-alkyyli-2-substituoituja ATP-analogeja - Google Patents

Menetelmä valmistaa N-alkyyli-2-substituoituja ATP-analogeja Download PDF

Info

Publication number: FI110687B
Authority: FI; Finland
Prior art keywords: acid; propylthio; adenylic; bisphosphonic acid; formula
Prior art date: 1993-02-10

Application number

FI953794A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI953794A0 (fi

FI953794L (fi

Inventor

Anthony Howard Ingall

Peter Alan Cage

Nicholas David Kindon

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-02-10

Filing date

1995-08-10

Publication date

2003-03-14

1993-02-10 Priority claimed from GB939302636A external-priority patent/GB9302636D0/en

1993-12-16 Priority claimed from GB939325712A external-priority patent/GB9325712D0/en

1995-08-10 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

1995-08-10 Publication of FI953794A0 publication Critical patent/FI953794A0/fi

1995-08-10 Publication of FI953794L publication Critical patent/FI953794L/fi

2003-03-14 Application granted granted Critical

2003-03-14 Publication of FI110687B publication Critical patent/FI110687B/fi

Links

238000000034 method Methods 0.000 title claims abstract description 29
230000008569 process Effects 0.000 title claims abstract description 12
238000002360 preparation method Methods 0.000 title claims description 6
150000001875 compounds Chemical class 0.000 claims abstract description 72
150000003839 salts Chemical class 0.000 claims abstract description 61
125000000217 alkyl group Chemical group 0.000 claims abstract description 10
229910052736 halogen Inorganic materials 0.000 claims abstract description 10
150000002367 halogens Chemical class 0.000 claims abstract description 10
230000002378 acidificating effect Effects 0.000 claims abstract description 7
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 4
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 4
239000001257 hydrogen Substances 0.000 claims abstract description 4
125000001424 substituent group Chemical group 0.000 claims abstract description 4
ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims description 39
-1 NR 6 R 7 Chemical group 0.000 claims description 21
150000008064 anhydrides Chemical class 0.000 claims description 17
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
229950006790 adenosine phosphate Drugs 0.000 claims description 5
125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 4
101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 claims description 4
125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 3
125000000524 functional group Chemical group 0.000 claims description 3
MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical compound OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 claims description 3
239000007858 starting material Substances 0.000 claims description 3
238000010511 deprotection reaction Methods 0.000 claims description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
JDPCURMUPKTBTH-SDBHATRESA-N [(2r,3s,4r,5r)-3,4-dihydroxy-5-[6-(2-methoxyethylamino)-2-propylsulfanylpurin-9-yl]oxolan-2-yl]methyl dihydrogen phosphate Chemical compound C12=NC(SCCC)=NC(NCCOC)=C2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O JDPCURMUPKTBTH-SDBHATRESA-N 0.000 claims 1
KVLRBRZHCOVMNX-IDTAVKCVSA-N [(2r,3s,4r,5r)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methyl dihydrogen phosphate Chemical compound C1=NC=2C(NCCSC)=NC(SCCC(F)(F)F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O KVLRBRZHCOVMNX-IDTAVKCVSA-N 0.000 claims 1
ZUFVMKXSAZYDKM-SDBHATRESA-N [(2r,3s,4r,5r)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-propylsulfanylpurin-9-yl]oxolan-2-yl]methyl dihydrogen phosphate Chemical compound C12=NC(SCCC)=NC(NCCSC)=C2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O ZUFVMKXSAZYDKM-SDBHATRESA-N 0.000 claims 1
XDSNOQOPQLENAB-SDBHATRESA-N [(2r,3s,4r,5r)-3,4-dihydroxy-5-[6-(propan-2-ylamino)-2-propylsulfanylpurin-9-yl]oxolan-2-yl]methyl dihydrogen phosphate Chemical compound C12=NC(SCCC)=NC(NC(C)C)=C2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O XDSNOQOPQLENAB-SDBHATRESA-N 0.000 claims 1
VEDLSCXXQYDSKL-SDBHATRESA-N [(2r,3s,4r,5r)-3,4-dihydroxy-5-[6-(propylamino)-2-propylsulfanylpurin-9-yl]oxolan-2-yl]methyl dihydrogen phosphate Chemical compound C1=NC=2C(NCCC)=NC(SCCC)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O VEDLSCXXQYDSKL-SDBHATRESA-N 0.000 claims 1
MZTWOBWCXQBOQX-LSCFUAHRSA-N [(2r,3s,4r,5r)-5-[2-cyclohexylsulfanyl-6-(ethylamino)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound N=1C=2N([C@H]3[C@@H]([C@H](O)[C@@H](COP(O)(O)=O)O3)O)C=NC=2C(NCC)=NC=1SC1CCCCC1 MZTWOBWCXQBOQX-LSCFUAHRSA-N 0.000 claims 1
DHVIOSFPNMWJMT-XNIJJKJLSA-N [(2r,3s,4r,5r)-5-[6-(butylamino)-2-propylsulfanylpurin-9-yl]-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound C1=NC=2C(NCCCC)=NC(SCCC)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O DHVIOSFPNMWJMT-XNIJJKJLSA-N 0.000 claims 1
JBDZVBMJDOZVID-LSCFUAHRSA-N [(2r,3s,4r,5r)-5-[6-(cyclopentylamino)-2-propylsulfanylpurin-9-yl]-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound C=12N=CN([C@H]3[C@@H]([C@H](O)[C@@H](COP(O)(O)=O)O3)O)C2=NC(SCCC)=NC=1NC1CCCC1 JBDZVBMJDOZVID-LSCFUAHRSA-N 0.000 claims 1
CQXHZLYQRRWZCJ-QYVSTXNMSA-N [(2r,3s,4r,5r)-5-[6-(ethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound C1=NC=2C(NCC)=NC(SCCC(F)(F)F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O CQXHZLYQRRWZCJ-QYVSTXNMSA-N 0.000 claims 1
ASMDXUAEALRSSY-IDTAVKCVSA-N [(2r,3s,4r,5r)-5-[6-(ethylamino)-2-propylsulfanylpurin-9-yl]-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound C12=NC(SCCC)=NC(NCC)=C2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O ASMDXUAEALRSSY-IDTAVKCVSA-N 0.000 claims 1
PFBUKDPBVNJDEW-UHFFFAOYSA-N dichlorocarbene Chemical group Cl[C]Cl PFBUKDPBVNJDEW-UHFFFAOYSA-N 0.000 claims 1
CHQATWSHFXGCBC-PMXXHBEXSA-N methyl 2-[[9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]-2-propylsulfanylpurin-6-yl]amino]acetate Chemical compound C12=NC(SCCC)=NC(NCC(=O)OC)=C2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O CHQATWSHFXGCBC-PMXXHBEXSA-N 0.000 claims 1
125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 6
239000008194 pharmaceutical composition Substances 0.000 abstract description 4
238000004519 manufacturing process Methods 0.000 abstract description 3
125000004414 alkyl thio group Chemical group 0.000 abstract 1
239000000243 solution Substances 0.000 description 33
239000002253 acid Substances 0.000 description 31
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 18
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 12
239000003480 eluent Substances 0.000 description 12
230000002776 aggregation Effects 0.000 description 11
238000004220 aggregation Methods 0.000 description 11
230000000694 effects Effects 0.000 description 11
XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 10
XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 10
239000000047 product Substances 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical class C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
239000000203 mixture Substances 0.000 description 8
238000000746 purification Methods 0.000 description 8
239000000725 suspension Substances 0.000 description 8
239000002126 C01EB10 - Adenosine Substances 0.000 description 7
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
229960005305 adenosine Drugs 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
238000004587 chromatography analysis Methods 0.000 description 6
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
230000004044 response Effects 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
239000000556 agonist Substances 0.000 description 5
239000000460 chlorine Substances 0.000 description 5
238000001802 infusion Methods 0.000 description 5
239000002777 nucleoside Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 5
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
229920005654 Sephadex Polymers 0.000 description 4
239000012507 Sephadex™ Substances 0.000 description 4
230000007062 hydrolysis Effects 0.000 description 4
238000006460 hydrolysis reaction Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
210000004623 platelet-rich plasma Anatomy 0.000 description 4
KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 4
125000006239 protecting group Chemical group 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
DUNWGJPJYFSUBZ-IOSLPCCCSA-N (2r,3r,4s,5r)-2-(6-amino-2-methylpurin-9-yl)-5-(dihydroxyphosphinothioyloxymethyl)oxolane-3,4-diol Chemical compound C12=NC(C)=NC(N)=C2N=CN1[C@@H]1O[C@H](COP(O)(O)=S)[C@@H](O)[C@H]1O DUNWGJPJYFSUBZ-IOSLPCCCSA-N 0.000 description 3
UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 3
125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical class NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 3
101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229910004298 SiO 2 Inorganic materials 0.000 description 3
229960000583 acetic acid Drugs 0.000 description 3
125000002252 acyl group Chemical group 0.000 description 3
238000007792 addition Methods 0.000 description 3
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
235000012538 ammonium bicarbonate Nutrition 0.000 description 3
239000001099 ammonium carbonate Substances 0.000 description 3
125000005002 aryl methyl group Chemical group 0.000 description 3
239000002585 base Substances 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
229910052801 chlorine Inorganic materials 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
238000001816 cooling Methods 0.000 description 3
239000012043 crude product Substances 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
125000003835 nucleoside group Chemical group 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
239000012074 organic phase Substances 0.000 description 3
229910000027 potassium carbonate Inorganic materials 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
239000011734 sodium Substances 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
229910000104 sodium hydride Inorganic materials 0.000 description 3
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
238000012360 testing method Methods 0.000 description 3
IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 3
AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 2
LXJSJIXZOAMHTG-UHFFFAOYSA-N 4-(1,3-dimethyl-2,6-dioxo-7h-purin-8-yl)benzenesulfonic acid Chemical compound N1C=2C(=O)N(C)C(=O)N(C)C=2N=C1C1=CC=C(S(O)(=O)=O)C=C1 LXJSJIXZOAMHTG-UHFFFAOYSA-N 0.000 description 2
JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 2
241000700199 Cavia porcellus Species 0.000 description 2
UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
101150112132 PAP4 gene Proteins 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
150000003973 alkyl amines Chemical class 0.000 description 2
150000003863 ammonium salts Chemical class 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
229940127219 anticoagulant drug Drugs 0.000 description 2
229940127218 antiplatelet drug Drugs 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
230000030609 dephosphorylation Effects 0.000 description 2
238000006209 dephosphorylation reaction Methods 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
208000009190 disseminated intravascular coagulation Diseases 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000001640 fractional crystallisation Methods 0.000 description 2
238000007327 hydrogenolysis reaction Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000008101 lactose Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
125000002757 morpholinyl group Chemical group 0.000 description 2
150000003833 nucleoside derivatives Chemical class 0.000 description 2
239000003921 oil Substances 0.000 description 2
239000000106 platelet aggregation inhibitor Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000002265 prevention Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000010992 reflux Methods 0.000 description 2
239000000523 sample Substances 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000003419 tautomerization reaction Methods 0.000 description 2
125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
DQWPFSLDHJDLRL-UHFFFAOYSA-N triethyl phosphate Chemical compound CCOP(=O)(OCC)OCC DQWPFSLDHJDLRL-UHFFFAOYSA-N 0.000 description 2
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
DWLALUFKMWICHD-SCFUHWHPSA-N (2r,3r,4s,5r)-2-(6-anilino-2-propylsulfanylpurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=12N=CN([C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C2=NC(SCCC)=NC=1NC1=CC=CC=C1 DWLALUFKMWICHD-SCFUHWHPSA-N 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
ZPIFKCVYZBVZIV-UHFFFAOYSA-N 3-chloro-1,1,1-trifluoropropane Chemical compound FC(F)(F)CCCl ZPIFKCVYZBVZIV-UHFFFAOYSA-N 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
206010002388 Angina unstable Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
ODHAQPXNQDBHSH-UHFFFAOYSA-N Dicyclohexyl disulfide Chemical compound C1CCCCC1SSC1CCCCC1 ODHAQPXNQDBHSH-UHFFFAOYSA-N 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
206010014498 Embolic stroke Diseases 0.000 description 1
206010014513 Embolism arterial Diseases 0.000 description 1
235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
244000166102 Eucalyptus leucoxylon Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000032984 Intraoperative Complications Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229910014288 N-N Inorganic materials 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
229910014320 N—N Inorganic materials 0.000 description 1
108091007262 P2T receptors Proteins 0.000 description 1
101000882917 Penaeus paulensis Hemolymph clottable protein Proteins 0.000 description 1
208000018262 Peripheral vascular disease Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
108010080192 Purinergic Receptors Proteins 0.000 description 1
102000000033 Purinergic Receptors Human genes 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
208000007814 Unstable Angina Diseases 0.000 description 1
208000035868 Vascular inflammations Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
MIANKMUJBVQUGT-SCFUHWHPSA-N [(2r,3r,4r,5r)-3,4-diacetyloxy-5-(6-chloro-2-propylsulfanylpurin-9-yl)oxolan-2-yl]methyl acetate Chemical compound C12=NC(SCCC)=NC(Cl)=C2N=CN1[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H]1OC(C)=O MIANKMUJBVQUGT-SCFUHWHPSA-N 0.000 description 1
FXXRIUZMLRLFKP-UUOKFMHZSA-N [(2r,3s,4r,5r)-5-(6-amino-2-chloropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O FXXRIUZMLRLFKP-UUOKFMHZSA-N 0.000 description 1
LPUNOWSWFBIBQH-JVXRWYCYSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl] dihydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=S)OP(O)(O)=O)[C@@H](O)[C@H]1O LPUNOWSWFBIBQH-JVXRWYCYSA-N 0.000 description 1
HSRBLOWVRMGXEC-UHFFFAOYSA-N [difluoro(phosphono)methyl]phosphonic acid Chemical compound OP(O)(=O)C(F)(F)P(O)(O)=O HSRBLOWVRMGXEC-UHFFFAOYSA-N 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
229940040526 anhydrous sodium acetate Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
208000021328 arterial occlusion Diseases 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000010945 base-catalyzed hydrolysis reactiony Methods 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
150000007516 brønsted-lowry acids Chemical class 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
230000002612 cardiopulmonary effect Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
230000035602 clotting Effects 0.000 description 1
238000004040 coloring Methods 0.000 description 1
125000005265 dialkylamine group Chemical group 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
125000003963 dichloro group Chemical group Cl* 0.000 description 1
WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
LTVOKYUPTHZZQH-UHFFFAOYSA-N difluoromethane Chemical group F[C]F LTVOKYUPTHZZQH-UHFFFAOYSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
238000001035 drying Methods 0.000 description 1
108010047482 ectoATPase Proteins 0.000 description 1
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
150000002081 enamines Chemical class 0.000 description 1
229960001123 epoprostenol Drugs 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000002337 glycosamines Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229940106780 human fibrinogen Drugs 0.000 description 1
AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000002631 hypothermal effect Effects 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
150000002466 imines Chemical class 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
201000004332 intermediate coronary syndrome Diseases 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
238000002955 isolation Methods 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
230000000865 phosphorylative effect Effects 0.000 description 1
238000006303 photolysis reaction Methods 0.000 description 1
230000015843 photosynthesis, light reaction Effects 0.000 description 1
229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
239000000843 powder Substances 0.000 description 1
201000011461 pre-eclampsia Diseases 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
SUVIGLJNEAMWEG-UHFFFAOYSA-N propane-1-thiol Chemical compound CCCS SUVIGLJNEAMWEG-UHFFFAOYSA-N 0.000 description 1
239000003586 protic polar solvent Substances 0.000 description 1
239000008213 purified water Substances 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000006340 racemization Effects 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000003352 sequestering agent Substances 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
235000009518 sodium iodide Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000008736 traumatic injury Effects 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
125000004417 unsaturated alkyl group Chemical group 0.000 description 1
230000002792 vascular Effects 0.000 description 1
239000001993 wax Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

FI953794A 1993-02-10 1995-08-10 Menetelmä valmistaa N-alkyyli-2-substituoituja ATP-analogeja FI110687B (fi)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
GB939302636A GB9302636D0 (en)	1993-02-10	1993-02-10	Compounds
GB9302636		1993-02-10
GB939325712A GB9325712D0 (en)	1993-12-16	1993-12-16	Compounds
GB9325712		1993-12-16
GB9400237		1994-02-08
PCT/GB1994/000237 WO1994018216A1 (fr)	1993-02-10	1994-02-08	Analogues d'adenosine triphosphate (atb) substitues en position 2 par n-alkyle

Publications (3)

Publication Number	Publication Date
FI953794A0 FI953794A0 (fi)	1995-08-10
FI953794L FI953794L (fi)	1995-08-10
FI110687B true FI110687B (fi)	2003-03-14

Family

ID=26302434

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI953794A FI110687B (fi)	1993-02-10	1995-08-10	Menetelmä valmistaa N-alkyyli-2-substituoituja ATP-analogeja

Country Status (25)

Country	Link
US (2)	US5721219A (fr)
EP (1)	EP0683789B1 (fr)
JP (1)	JP3083156B2 (fr)
KR (1)	KR100315612B1 (fr)
CN (1)	CN1042430C (fr)
AT (1)	ATE159950T1 (fr)
AU (1)	AU679721B2 (fr)
CA (1)	CA2155673C (fr)
CZ (1)	CZ286050B6 (fr)
DE (1)	DE69406649T2 (fr)
DK (1)	DK0683789T3 (fr)
ES (1)	ES2108425T3 (fr)
FI (1)	FI110687B (fr)
GR (1)	GR3025995T3 (fr)
HU (1)	HU221501B (fr)
IL (1)	IL108602A (fr)
NO (1)	NO305209B1 (fr)
NZ (1)	NZ261159A (fr)
PL (1)	PL175623B1 (fr)
RU (1)	RU2136693C1 (fr)
SG (1)	SG47943A1 (fr)
SK (1)	SK281309B6 (fr)
TW (1)	TW326045B (fr)
UA (1)	UA54366C2 (fr)
WO (1)	WO1994018216A1 (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK281309B6 (sk) *	1993-02-10	2001-02-12	Astra Pharmaceuticals Limited	N-alkyl-2-substituované adenozíntrifosfátové deriváty, spôsob ich prípravy, farmaceutické prostriedky obsahujúce tieto deriváty a použitie týchto derivátov
EP0929218A4 (fr) *	1996-10-30	2001-05-16	Univ North Carolina	Antagonistes des recepteurs p2y
ID21635A (id) *	1996-12-20	1999-07-08	Astra Pharma Prod	Komposisi farmasi untuk pengeringan beku
US6686462B2 (en) *	1997-02-28	2004-02-03	The Regents Of The University Of California	Antiviral compounds and methods of administration
AU2003257524B2 (en) *	1997-07-11	2006-04-06	Astrazeneca Ab	New formulation
SE9702680D0 (sv) *	1997-07-11	1997-07-11	Astra Pharma Prod	New formulation
FI104901B (fi) *	1997-10-20	2000-04-28	Leiras Oy	Uudet metyleenibisfosfonihappojohdannaiset
US8586781B2 (en)	1998-04-02	2013-11-19	Mbc Pharma, Inc.	Bone targeted therapeutics and methods of making and using the same
US6750340B2 (en) *	1998-04-02	2004-06-15	Mbc Research, Inc.	Bisphosphonate conjugates and methods of making and using the same
US7598246B2 (en) *	1998-04-02	2009-10-06	Mbc Pharma, Inc.	Bisphosphonate conjugates and methods of making and using the same
TWI229674B (en)	1998-12-04	2005-03-21	Astra Pharma Prod	Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US7205404B1 (en) *	1999-03-05	2007-04-17	Metabasis Therapeutics, Inc.	Phosphorus-containing prodrugs
US6303774B1 (en)	1999-08-20	2001-10-16	Sri International	Nucleoside pyrophosphate and triphosphate analogs and related compounds
SE9903345D0 (sv)	1999-09-17	1999-09-17	Astra Pharma Prod	Novel process
SE9904377D0 (sv) *	1999-12-01	1999-12-01	Astra Pharma Prod	Pharmaceutical combinations
US7452870B2 (en)	2000-08-21	2008-11-18	Inspire Pharmaceuticals, Inc.	Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7132408B2 (en)	2000-08-21	2006-11-07	Inspire Pharmaceuticals, Inc.	Composition and method for inhibiting platelet aggregation
AR039558A1 (es) *	2000-08-21	2005-02-23	Inspire Pharmaceuticals Inc	Composiciones y metodo para el tratamiento de glaucoma o hipertension ocular
US6897201B2 (en)	2000-08-21	2005-05-24	Inspire Pharmaceuticals, Inc.	Compositions and methods for the treatment of glaucoma or ocular hypertension
US6867199B2 (en)	2000-08-21	2005-03-15	Inspire Pharmaceuticals, Inc.	Dinucleoside polyphosphate compositions and their therapeutic use
US7115585B2 (en)	2000-08-21	2006-10-03	Inspire Pharmaceuticals, Inc.	Compositions for treating epithelial and retinal tissue diseases
US7018985B1 (en)	2000-08-21	2006-03-28	Inspire Pharmaceuticals, Inc.	Composition and method for inhibiting platelet aggregation
US7435724B2 (en)	2002-02-27	2008-10-14	Inspire Pharmaceutical, Inc.	Degradation-resistant mononucleoside phosphate compounds
RU2004128943A (ru) *	2002-02-28	2005-04-20	Байота, Инк. (Us)	Средства, имитирующие нуклеотиды, и их пролекарственные формы
AU2003248077A1 (en) *	2002-07-18	2004-02-09	Sankyo Company, Limited	Medicinal composition for treating arteriosclerosis
US20050192245A1 (en) *	2002-07-18	2005-09-01	Sankyo Company, Limited	Medicinal composition for treating arteriosclerosis
NZ539796A (en)	2002-11-21	2006-11-30	Kowa Co	Peritoneal dialysis method comprising adenosine triphosphate
US8293890B2 (en) *	2004-04-30	2012-10-23	Advanced Cardiovascular Systems, Inc.	Hyaluronic acid based copolymers
EP1604669A1 (fr) *	2004-06-10	2005-12-14	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Utilisation d'analogues de l'ATP pour le traitement de maladies cardiovasculaires
WO2009140092A1 (fr)	2008-05-13	2009-11-19	The Medicines Company	Conservation de l'inhibition de plaquettes durant une thérapie anti-plaquettes
US8759316B2 (en) *	2008-05-13	2014-06-24	The Medicines Company	Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) *	2008-05-13	2012-06-07	Lisa Ruderman Chen	Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) *	2008-05-13	2013-11-14	The Medicines Company	Maintenance of Platelet Inhibition During Antiplatelet Therapy
US9427448B2 (en)	2009-11-11	2016-08-30	The Medicines Company	Methods of treating, reducing the incidence of, and/or preventing ischemic events
US10376532B2 (en)	2009-11-11	2019-08-13	Chiesi Farmaceutici, S.P.A.	Methods of treating, reducing the incidence of, and/or preventing ischemic events
PT2498731T (pt) *	2009-11-11	2020-02-21	Chiesi Farm Spa	Métodos de tratamento ou prevenção de uma trombose de endoprótese
WO2012100654A1 (fr) *	2011-01-26	2012-08-02	北京化工大学	Composé de ribofuranosyl-purine, procédé de préparation pour celui-ci, et utilisation de celui-ci
AU2012214396B2 (en) *	2011-02-09	2017-04-27	Chiesi Farmaceutici S.P.A.	Methods for treating pulmonary hypertension
CA2843885C (fr)	2011-08-01	2020-03-10	Mbc Pharma, Inc.	Derives a base de vitamine b6 de nucleotides, d'acyclonucleotides et de phosphonates d'acyclonucleosides
BR112015022070B1 (pt)	2013-03-09	2022-01-18	Chiesi Farmaceutici S.P.A.	Uso de cangrelor
CN104447928A (zh) *	2013-09-13	2015-03-25	天津市汉康医药生物技术有限公司	坎格雷洛二水化合物
CN104447927A (zh) *	2013-09-13	2015-03-25	天津市汉康医药生物技术有限公司	坎格雷洛一水合物晶体及其制备方法
CN103772461A (zh) *	2014-01-06	2014-05-07	南京正科制药有限公司	一种坎格雷洛晶型ⅰ
JP2017512183A (ja)	2014-02-13	2017-05-18	リガンド・ファーマシューティカルズ・インコーポレイテッド	プロドラッグ化合物およびそれらの使用
CN106687118A (zh)	2014-07-02	2017-05-17	配体药物公司	前药化合物及其用途
CN105273025B (zh) *	2014-07-22	2019-07-26	上海医药工业研究院	一种制备坎格雷洛的中间体及其制备方法和应用
EP3244900A4 (fr)	2015-01-14	2018-05-30	Chiesi Farmaceutici S.p.A.	Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation
CN105061431B (zh) *	2015-07-28	2017-03-29	山东百诺医药股份有限公司	6‑n‑（2‑（甲硫基）乙基）‑2‑（（3,3,3‑三氟丙基）硫代）‑9h‑嘌呤及其制备方法和应用
CN107001405B (zh) *	2015-11-06	2019-03-05	江苏恒瑞医药股份有限公司	制备坎格雷洛中间体的方法
CN107973798B (zh) *	2016-10-25	2020-04-24	上海医药工业研究院	2-[(3,3,3-三氟丙基)硫代]-6-氨基-9h-嘌呤及制法
CN107973832B (zh) *	2016-10-25	2021-11-12	上海医药工业研究院	6-n-[2-(甲硫基)乙基]-2-[(3，3，3-三氟丙基)硫代]腺苷的制法
CN106674322B (zh) *	2016-12-07	2019-04-16	上海博志研新药物技术有限公司	一种坎格雷洛中间体的纯化方法
WO2018185715A1 (fr) *	2017-04-06	2018-10-11	Msn Laboratories Private Limited, R&D Center	Procédé amélioré pour la préparation d'un monoanhydride de l'acide n6-[2-(méthylthio)éthyl]-2-[(3,3,3-trifluoropropyl)thio]-5'-adénylique avec de l'acide (dichlorométhylène)bisphosphonique et de ses sels pharmaceutiquement acceptables
US11260071B2 (en)	2017-06-23	2022-03-01	Chiesi Farmaceutici S.P.A.	Method of preventing of systemic-to-pulmonary-artery shunt thrombosis
WO2019092546A1 (fr) *	2017-11-10	2019-05-16	Olon S.P.A.	Procédé efficace de préparation de cangrelor
CN109912674A (zh) *	2017-12-12	2019-06-21	亚宝药业集团股份有限公司	一种坎格雷洛四钠盐的制备方法
RU2020126177A (ru)	2018-01-09	2022-02-10	Лиганд Фармасьютикалз, Инк.	Ацетальные соединения и их терапевтическое применение
US20190241606A1 (en) *	2018-02-05	2019-08-08	Scinopharm Taiwan, Ltd.	Process for preparation of cangrelor tetrasodium and intermediate therefor
CN108033983B (zh) *	2018-02-09	2021-06-08	盐城锦明药业有限公司	一种2‐(3,3,3‐三氟丙基)硫代腺苷的合成方法
EP4289435A1 (fr)	2022-06-07	2023-12-13	Université de Liège	Analogues atp n-alkyl-2-substitués pour utilisation comme agent antibactérien

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU764326A1 (ru) *	1977-11-16	1982-09-23	Ордена Ленина Институт Химической Физики Ан Ссср	Способ получени спин-меченого производного аденозинтрифосфата
US5049550A (en) *	1987-11-05	1991-09-17	Worcester Foundation For Experimental Biology	Diadenosine 5', 5'"-p1, p4,-tetraphosphate analogs as antithrombotic agents
CA2049977A1 (fr) *	1989-03-24	1990-09-25	Hirofumi Kitaoka	Agent nootropique
EP0508687B1 (fr) *	1991-04-06	1995-09-13	Astra Pharmaceuticals Limited	Analogues d'ADP
GB9107236D0 (en)	1991-04-06	1991-05-22	Fisons Plc	Compounds
SK281309B6 (sk) *	1993-02-10	2001-02-12	Astra Pharmaceuticals Limited	N-alkyl-2-substituované adenozíntrifosfátové deriváty, spôsob ich prípravy, farmaceutické prostriedky obsahujúce tieto deriváty a použitie týchto derivátov

1994
- 1994-02-08 SK SK994-95A patent/SK281309B6/sk not_active IP Right Cessation
- 1994-02-08 JP JP06517805A patent/JP3083156B2/ja not_active Expired - Lifetime
- 1994-02-08 KR KR1019950703322A patent/KR100315612B1/ko not_active Expired - Lifetime
- 1994-02-08 DK DK94905810.1T patent/DK0683789T3/da active
- 1994-02-08 NZ NZ261159A patent/NZ261159A/en not_active IP Right Cessation
- 1994-02-08 ES ES94905810T patent/ES2108425T3/es not_active Expired - Lifetime
- 1994-02-08 RU RU95118285/04A patent/RU2136693C1/ru active
- 1994-02-08 PL PL94310160A patent/PL175623B1/pl unknown
- 1994-02-08 DE DE69406649T patent/DE69406649T2/de not_active Expired - Lifetime
- 1994-02-08 CA CA002155673A patent/CA2155673C/fr not_active Expired - Lifetime
- 1994-02-08 CN CN94191559A patent/CN1042430C/zh not_active Expired - Lifetime
- 1994-02-08 SG SG1996005584A patent/SG47943A1/en unknown
- 1994-02-08 WO PCT/GB1994/000237 patent/WO1994018216A1/fr not_active Ceased
- 1994-02-08 AT AT94905810T patent/ATE159950T1/de active
- 1994-02-08 EP EP94905810A patent/EP0683789B1/fr not_active Expired - Lifetime
- 1994-02-08 AU AU59770/94A patent/AU679721B2/en not_active Expired
- 1994-02-08 HU HU9502348A patent/HU221501B/hu unknown
- 1994-02-08 TW TW083101092A patent/TW326045B/zh not_active IP Right Cessation
- 1994-02-08 CZ CZ952032A patent/CZ286050B6/cs not_active IP Right Cessation
- 1994-02-09 IL IL10860294A patent/IL108602A/en not_active IP Right Cessation
- 1994-08-02 UA UA95094059A patent/UA54366C2/uk unknown
1995
- 1995-08-09 NO NO953126A patent/NO305209B1/no not_active IP Right Cessation
- 1995-08-09 US US08/512,979 patent/US5721219A/en not_active Expired - Lifetime
- 1995-08-10 FI FI953794A patent/FI110687B/fi not_active IP Right Cessation
1997
- 1997-08-28 US US08/918,670 patent/US5955447A/en not_active Expired - Lifetime
1998
- 1998-01-26 GR GR980400166T patent/GR3025995T3/el unknown

Also Published As

Publication number	Publication date
JPH08506335A (ja)	1996-07-09
FI953794A0 (fi)	1995-08-10
SG47943A1 (en)	1998-04-17
AU5977094A (en)	1994-08-29
SK99495A3 (en)	1996-02-07
HK1002936A1 (en)	1998-09-25
ES2108425T3 (es)	1997-12-16
IL108602A (en)	1999-12-22
EP0683789B1 (fr)	1997-11-05
US5955447A (en)	1999-09-21
HUT72464A (en)	1996-04-29
CN1042430C (zh)	1999-03-10
TW326045B (en)	1998-02-01
CZ286050B6 (cs)	1999-12-15
DE69406649D1 (de)	1997-12-11
WO1994018216A1 (fr)	1994-08-18
PL310160A1 (en)	1995-11-27
DK0683789T3 (da)	1998-02-09
DE69406649T2 (de)	1998-03-05
NO953126D0 (no)	1995-08-09
UA54366C2 (uk)	2003-03-17
CA2155673A1 (fr)	1994-08-18
HU221501B (en)	2002-10-28
GR3025995T3 (en)	1998-04-30
KR100315612B1 (ko)	2002-06-20
EP0683789A1 (fr)	1995-11-29
NO953126L (no)	1995-09-28
US5721219A (en)	1998-02-24
SK281309B6 (sk)	2001-02-12
RU2136693C1 (ru)	1999-09-10
FI953794L (fi)	1995-08-10
CA2155673C (fr)	2004-08-17
JP3083156B2 (ja)	2000-09-04
ATE159950T1 (de)	1997-11-15
NO305209B1 (no)	1999-04-19
AU679721B2 (en)	1997-07-10
IL108602A0 (en)	1994-05-30
PL175623B1 (pl)	1999-01-29
CZ203295A3 (en)	1995-12-13
CN1119869A (zh)	1996-04-03
NZ261159A (en)	1997-06-24

Legal Events

Date	Code	Title	Description
2014-03-28	MA	Patent expired

Publication	Publication Date	Title
FI110687B (fi)	2003-03-14	Menetelmä valmistaa N-alkyyli-2-substituoituja ATP-analogeja
EP0508687B1 (fr)	1995-09-13	Analogues d'ADP
US4963662A (en)	1990-10-16	Fluorinated nucleosides and method for treating retrovirus infections therewith
US7018985B1 (en)	2006-03-28	Composition and method for inhibiting platelet aggregation
KR20070003993A (ko)	2007-01-05	혈소판 응집 억제 조성물 및 방법
HU221880B1 (hu)	2003-02-28	Vérlemezke-aggregáció inhibitorok, ezeket tartalmazó gyógyszerkészítmények és előállításuk
JP2009514604A (ja)	2009-04-09	Ｐ２ｙ１２受容体アンタゴニスト化合物でコートされた薬剤溶出ステント
US5654285A (en)	1997-08-05	ADP and ATP analogues, process for making and administration to inhibit ADP-induced platelet aggregation
US5153180A (en)	1992-10-06	Fluorinated nucleosides and process for treating retrovirus infections therewith
AU648885C (en)	1995-06-01	ATP analogues
HK1002936B (en)	1998-09-25	N-alkyl-2-substituted atp analogues
JPH02247191A (ja)	1990-10-02	抗レトロウイルス剤としてのプリンおよびピリミジン非環状ヌクレオシドの環状モノホスフエート類